Revolution Medicines

October 17, 2019

Triple meeting – clinical data, and competition, loom for Mirati

Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.

July 10, 2019

Redx sells another asset to keep the lights on

The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.

June 04, 2019

Asco 2019 – KRAS chase heats up with Amgen data

Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.

Revolution Medicines

Triple meeting – clinical data, and competition, loom for Mirati

Redx sells another asset to keep the lights on

Asco 2019 – KRAS chase heats up with Amgen data

Latest Reports

Vantage 2020 Preview

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Editor's Picks

What makes a great year for takeovers?

Surprise! There’s a tumour in which Keytruda doesn’t work

Gene therapy clinical holds take centre stage

Plenty of choice remains for buyers of gene therapy

Uncovering biopharma’s hidden treasures